139 related articles for article (PubMed ID: 35868778)
21. Understanding the role of colon-specific microparticles based on retrograded starch/pectin in the delivery of chitosan nanoparticles along the gastrointestinal tract.
Dos Santos AM; Meneguin AB; Akhter DT; Fletcher N; Houston ZH; Bell C; Thurecht KJ; Gremião MPD
Eur J Pharm Biopharm; 2021 Jan; 158():371-378. PubMed ID: 33309846
[TBL] [Abstract][Full Text] [Related]
22. Chitosan-based DDSs for pH/hypoxia dual-triggered DOX delivery: Facile morphology modulation for higher in vitro cytotoxicity.
Xie P; Liu P
Carbohydr Polym; 2022 Jan; 275():118760. PubMed ID: 34742449
[TBL] [Abstract][Full Text] [Related]
23. Enhanced Intracellular Delivery of Curcumin by Chitosan-Lipoic Acid as Reduction-Responsive Nanoparticles.
Rezaei S; Kashanian S; Bahrami Y; Zhaleh H; Cruz LJ
Curr Pharm Biotechnol; 2021; 22(5):622-635. PubMed ID: 32720599
[TBL] [Abstract][Full Text] [Related]
24. Dual drug-loaded biofunctionalized amphiphilic chitosan nanoparticles: Enhanced synergy between cisplatin and demethoxycurcumin against multidrug-resistant stem-like lung cancer cells.
Huang WT; Larsson M; Lee YC; Liu DM; Chiou GY
Eur J Pharm Biopharm; 2016 Dec; 109():165-173. PubMed ID: 27793756
[TBL] [Abstract][Full Text] [Related]
25. Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells.
Wang H; Agarwal P; Zhao S; Xu RX; Yu J; Lu X; He X
Biomaterials; 2015 Dec; 72():74-89. PubMed ID: 26344365
[TBL] [Abstract][Full Text] [Related]
26. Preparation of Modified Chitosan-based Nanoparticles for Efficient Delivery of Doxorubicin and/or Cisplatin to Breast Cancer Cells.
Matalqah SM; Aiedeh K; Mhaidat NM; Alzoubi KH; Al-Husein BA
Curr Cancer Drug Targets; 2022; 22(2):133-141. PubMed ID: 35081892
[TBL] [Abstract][Full Text] [Related]
27. Reduction Responsive Self-Assembled Nanoparticles Based on Disulfide-Linked Drug-Drug Conjugate with High Drug Loading and Antitumor Efficacy.
Song Q; Wang X; Wang Y; Liang Y; Zhou Y; Song X; He B; Zhang H; Dai W; Wang X; Zhang Q
Mol Pharm; 2016 Jan; 13(1):190-201. PubMed ID: 26629710
[TBL] [Abstract][Full Text] [Related]
28. Multilayer sodium alginate beads with porous core containing chitosan based nanoparticles for oral delivery of anticancer drug.
Li J; Jiang C; Lang X; Kong M; Cheng X; Liu Y; Feng C; Chen X
Int J Biol Macromol; 2016 Apr; 85():1-8. PubMed ID: 26724684
[TBL] [Abstract][Full Text] [Related]
29. Enhanced 4T1 breast carcinoma anticancer activity by co-delivery of doxorubicin and curcumin with core-shell drug-carrier based on heparin modified poly(L-lactide) grafted polyethylenimine cationic nanoparticles.
Guo O; Li X; Yang Y; Wei J; Zhao Q; Luo F; Qian Z
J Biomed Nanotechnol; 2014 Feb; 10(2):227-37. PubMed ID: 24738331
[TBL] [Abstract][Full Text] [Related]
30. Redox-Responsive and Dual-Targeting Hyaluronic Acid-Methotrexate Prodrug Self-Assembling Nanoparticles for Enhancing Intracellular Drug Self-Delivery.
Zhang Y; Li Y; Tian H; Zhu Q; Wang F; Fan Z; Zhou S; Wang X; Xie L; Hou Z
Mol Pharm; 2019 Jul; 16(7):3133-3144. PubMed ID: 31198046
[TBL] [Abstract][Full Text] [Related]
31. Stepwise pH-responsive nanoparticles for enhanced cellular uptake and on-demand intracellular release of doxorubicin.
Chen WL; Li F; Tang Y; Yang SD; Li JZ; Yuan ZQ; Liu Y; Zhou XF; Liu C; Zhang XN
Int J Nanomedicine; 2017; 12():4241-4256. PubMed ID: 28652730
[TBL] [Abstract][Full Text] [Related]
32. Development of enteric-coated, biphasic chitosan/HPMC microcapsules for colon-targeted delivery of anticancer drug-loaded nanoparticles.
Ma Y; Thurecht KJ; Coombes AGA
Int J Pharm; 2021 Sep; 607():121026. PubMed ID: 34418474
[TBL] [Abstract][Full Text] [Related]
33. mPEGylated solanesol micelles as redox-responsive nanocarriers with synergistic anticancer effect.
Qin B; Liu L; Wu X; Liang F; Hou T; Pan Y; Song S
Acta Biomater; 2017 Dec; 64():211-222. PubMed ID: 28963017
[TBL] [Abstract][Full Text] [Related]
34. Curcumin-loaded polymeric nanoparticles for enhanced anti-colorectal cancer applications.
Udompornmongkol P; Chiang BH
J Biomater Appl; 2015 Nov; 30(5):537-46. PubMed ID: 26170212
[TBL] [Abstract][Full Text] [Related]
35.
Du Z; Liu J; Zhang H; Wu X; Zhang B; Chen Y; Liu B; Ding L; Xiao H; Zhang T
J Agric Food Chem; 2019 Nov; 67(45):12511-12519. PubMed ID: 31626537
[TBL] [Abstract][Full Text] [Related]
36. Fabrication of self-assembled chitosan-dispersed LDL nanoparticles for drug delivery with a one-step green method.
Tian J; Xu S; Deng H; Song X; Li X; Chen J; Cao F; Li B
Int J Pharm; 2017 Jan; 517(1-2):25-34. PubMed ID: 27845214
[TBL] [Abstract][Full Text] [Related]
37. The effect of linkers on the self-assembling and anti-tumor efficacy of disulfide-linked doxorubicin drug-drug conjugate nanoparticles.
Wang Y; Wang X; Deng F; Zheng N; Liang Y; Zhang H; He B; Dai W; Wang X; Zhang Q
J Control Release; 2018 Jun; 279():136-146. PubMed ID: 29655991
[TBL] [Abstract][Full Text] [Related]
38. Functional Albumin Nanoformulations to Fight Adrenocortical Carcinoma: a Redox-Responsive Approach.
Curcio M; Avena P; Cirillo G; Casaburi I; Spizzirri UG; Nicoletta FP; Iemma F; Pezzi V
Pharm Res; 2020 Feb; 37(3):55. PubMed ID: 32060727
[TBL] [Abstract][Full Text] [Related]
39. Hypoxia-responsive folic acid conjugated glycol chitosan nanoparticle for enhanced tumor targeting treatment.
Jang EH; Shim MK; Kim GL; Kim S; Kang H; Kim JH
Int J Pharm; 2020 Apr; 580():119237. PubMed ID: 32201251
[TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo study of Gal-OS self-assembled nanoparticles for liver-targeting delivery of doxorubicin.
Guo H; Zhang D; Li T; Li C; Guo Y; Liu G; Hao L; Shen J; Qi L; Liu X; Luan J; Zhang Q
J Pharm Sci; 2014 Mar; 103(3):987-93. PubMed ID: 24549734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
